Pharmarise Holdings Corporation (TYO:2796)
Japan
· Delayed Price · Currency is JPY 479.00
-1.00 (-0.21%)
Jun 5, 2025, 3:30 PM JST
Pharmarise Holdings Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '25 Feb 28, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | May '20 May 31, 2020 | 2015 - 2019 |
| Revenue | 60,371 | 54,466 | 52,030 | 51,608 | 52,324 | 51,030 | Upgrade
|
| Revenue Growth (YoY) | 11.85% | 4.68% | 0.82% | -1.37% | 2.54% | -1.35% | Upgrade
|
| Cost of Revenue | 51,834 | 46,017 | 43,896 | 43,491 | 44,256 | 43,592 | Upgrade
|
| Gross Profit | 8,537 | 8,449 | 8,134 | 8,117 | 8,068 | 7,438 | Upgrade
|
| Selling, General & Admin | 5,225 | 4,371 | 3,728 | 3,525 | 3,659 | 3,462 | Upgrade
|
| Other Operating Expenses | 2,605 | 2,605 | 2,332 | 2,371 | 2,417 | 2,226 | Upgrade
|
| Operating Expenses | 8,387 | 7,533 | 6,695 | 6,596 | 6,821 | 6,402 | Upgrade
|
| Operating Income | 150 | 916 | 1,439 | 1,521 | 1,247 | 1,036 | Upgrade
|
| Interest Expense | -143 | -66 | -55 | -65 | -75 | -74 | Upgrade
|
| Interest & Investment Income | 8 | 1 | 2 | 2 | 2 | 2 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -17 | Upgrade
|
| Other Non Operating Income (Expenses) | -21 | -19 | 44 | 58 | 54 | 22 | Upgrade
|
| EBT Excluding Unusual Items | -6 | 832 | 1,430 | 1,516 | 1,228 | 969 | Upgrade
|
| Gain (Loss) on Sale of Investments | 7 | 19 | 30 | - | -4 | -119 | Upgrade
|
| Gain (Loss) on Sale of Assets | 18 | -1 | -4 | 2 | 61 | 111 | Upgrade
|
| Asset Writedown | -328 | -296 | -393 | -218 | -51 | -114 | Upgrade
|
| Other Unusual Items | -337 | -411 | -14 | 21 | -32 | -29 | Upgrade
|
| Pretax Income | -646 | 143 | 1,049 | 1,321 | 1,202 | 818 | Upgrade
|
| Income Tax Expense | 167 | 485 | 702 | 864 | 782 | 238 | Upgrade
|
| Earnings From Continuing Operations | -813 | -342 | 347 | 457 | 420 | 580 | Upgrade
|
| Minority Interest in Earnings | 13 | -9 | -14 | -10 | 6 | -3 | Upgrade
|
| Net Income | -800 | -351 | 333 | 447 | 426 | 577 | Upgrade
|
| Net Income to Common | -800 | -351 | 333 | 447 | 426 | 577 | Upgrade
|
| Net Income Growth | - | - | -25.50% | 4.93% | -26.17% | 2408.70% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 12 | 12 | 12 | 13 | Upgrade
|
| Shares Change (YoY) | 0.94% | -15.61% | 0.59% | 0.20% | -1.03% | 15.31% | Upgrade
|
| EPS (Basic) | -70.84 | -33.35 | 35.42 | 47.90 | 45.78 | 61.03 | Upgrade
|
| EPS (Diluted) | -70.85 | -33.35 | 26.86 | 36.22 | 34.59 | 46.32 | Upgrade
|
| EPS Growth | - | - | -25.83% | 4.70% | -25.31% | 1967.79% | Upgrade
|
| Free Cash Flow | - | 2,242 | 2,140 | 334 | 1,437 | 1,223 | Upgrade
|
| Free Cash Flow Per Share | - | 213.04 | 171.61 | 26.94 | 116.15 | 97.84 | Upgrade
|
| Dividend Per Share | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | 14.000 | Upgrade
|
| Gross Margin | 14.14% | 15.51% | 15.63% | 15.73% | 15.42% | 14.58% | Upgrade
|
| Operating Margin | 0.25% | 1.68% | 2.77% | 2.95% | 2.38% | 2.03% | Upgrade
|
| Profit Margin | -1.32% | -0.64% | 0.64% | 0.87% | 0.81% | 1.13% | Upgrade
|
| Free Cash Flow Margin | - | 4.12% | 4.11% | 0.65% | 2.75% | 2.40% | Upgrade
|
| EBITDA | 1,280 | 2,086 | 2,663 | 2,829 | 2,591 | 2,264 | Upgrade
|
| EBITDA Margin | 2.12% | 3.83% | 5.12% | 5.48% | 4.95% | 4.44% | Upgrade
|
| D&A For EBITDA | 1,130 | 1,170 | 1,224 | 1,308 | 1,344 | 1,228 | Upgrade
|
| EBIT | 150 | 916 | 1,439 | 1,521 | 1,247 | 1,036 | Upgrade
|
| EBIT Margin | 0.25% | 1.68% | 2.77% | 2.95% | 2.38% | 2.03% | Upgrade
|
| Effective Tax Rate | - | 339.16% | 66.92% | 65.41% | 65.06% | 29.09% | Upgrade
|
Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.